Management & Board

Management (Update in progress)

Anja E. H. Holm


Anja Holm has substantial experience in European regulation of veterinary medicines, including clinical trials, authorization procedures and legislation, and in international negotiations. She worked in the Committee for Veterinary Medicines (CVMP) under the European Medicines Agency for 12 years, including 6 years as Chairperson, with innovative veterinary medicines, gene technology and vaccines. At the Danish Medicines Agency, she was senior scientific officer in veterinary medicine for 18 years and latest held the position as Head of unit for clinical trials.
Early in her career she practiced as a veterinarian for four years and participated in a DNA-vaccine research project at the Danish Virus Institute. Anja holds a degree as Doctor of Veterinary Medicine (DVM) from Copenhagen.

Carlos N. Velez

 Director Business Development

Carlos Velez has direct experience in the sourcing, evaluation, and licensing of novel products, including animal health assets. He was previously the Chief Business Officer (CBO) of Lantix Therapeutics UK and has been Director of Business Development at Penwest Pharmaceuticals, where he was responsible for the out-licensing of 505(b)(2) programs as well as the scouting and analysis of neurology in-licensing opportunities. Other previous employers include Forest Labs, Frankel Group (now Huron Consulting) and Genencor International. Carlos holds a B.Sc. in Pharmacy from the Albany College of Pharmacy, a Ph.D. in Pharmacy from the University of North Carolina at Chapel Hill, and an MBA in Finance from the Rochester Institute of Technology.

Katarina Holm

Chief Financial Officer

The new CFO for Panion Animal Health AB from the of November 2018 is Katarina Holm.
Katarina Holm has a broad experience in accounting and financial controlling. She has previously worked at ER Redovisning in Lund and as accountant for Mazars in Sweden. She holds a degree in economics (civil-ekonom) from Lund university.

Despite identical last name, she has no family relation to the CEO of the company.



Board (Update in progress)

Lars Thunberg

Chairman of the Board

Lars Thunberg, born 1966, is a co-founder of CombiGene and chaired its board during the period Aug. 2013 to Oct. 2014. He has for many years served as board member or chairman of several companies, including some listed on the stock market. He has been the chairman of Panion since the beginning and is one of the largest share owners. Lars holds an MSc in Business Administration and Economics from Stockholm University and Lund University.

Dede Willis

Board member

Dede Willis has over 30 years of international experience in start-ups and turn-arounds. She has expertise in strategic planning & execution, acquisition negotiation & integration, product development from concept to commercialization, FDA and CE Marking regulatory processes for drugs & devices, as well as sales & marketing.  Dede Willis spent the first 15 years of her career with the former Hoechst Group (now Sanofi, Celanese, and DuPont) where she worked in several corporate start-ups in the U.S. and Germany. Her last position with the Hoechst Group was President and CEO of a large subsidiary. She has managed the development and launch of multiple products including medical devices and veterinary diagnostics. She was co-founder, COO and Board Member of Boulder Diagnostics Inc, whose technology was acquired by Oxford Immunotec. She was responsible for the development and launch of veterinary diagnostic products for Lyme disease and parasite detection.  Dede holds a B.Sc. in Chemical engineering from Clemson University and an MBA from the University of Houston.

Lars Friis Mikkelsen

Board member

Lars Friis Mikkelsen is an experienced in-vivo pharmacology experts. He is the CEO of Ellegaard Göttingen Minipigs that produces experimental pigs for research purposes. He is also the founder of the company LarSolution that offers advice on pharmacological development and business development in the pharmaceutical field. Lars worked with pharmacology and experimental animals, including animal protection and welfare, for many years in Novo Nordisk and MSD/Merck, latest as Head of in-vivo pharmacology. Early in his career he worked as a veterinary practitioner in Rønde, Denmark. He is a Board member of the European Animal Research Association (EARA) and Chairman of the Large Animals Topic Group, European Federation of Pharmaceutical Industries and Associations (EFPIA). Lars holds a Doctor of Veterinary Medicines degree (DVM) from Copenhagen, 1994.

Nerry Kamstrup

Board member

Nerry Kamstrup is an experienced veterinary practitioner and has extensive expertise from animal clinics in Fakse, Vordingborg and Husum. She worked in several countries, e.g. in Maryland, USA, where she served as expert in ophthalmology (eye diseases) at a companion animal clinic. Nerry is authorised by the Danish veterinary eye-disease panel since 2006 and has a great passion for treatment and surgery of eye diseases in all animal species. She is also certified by The European College of Veterinary Ophthalmologists (ECVO), which requires that she participates in many courses and congresses within the field of eye diseases. Nerry holds a degree as Doctor of Veterinary Medicine (DVM) from Copenhagen.